Sign In
Section Navigation
Common TitleGS-380-4030
Official Title A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects Who Are Virologically Suppressed
Phase Phase III
ClinicalTrials.gov NCT03110380
Treatments
Bictegravir-Tenofovir alafenamide-Emtricitabine
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy

Bictegravir-Tenofovir alafenamide-Emtricitabine

Tradename:BiktarvyOther Names:BIC-TAF-FTCClass:Single-Tablet Regimens
Categories Treatment-ExperiencedSwitch/Simplification
Funding
IndustryGilead Sciences
References
  • Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021;73:e485-e493.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.